CN112891640A - 一种Zn-Mg系锌合金血管支架及其制备方法 - Google Patents
一种Zn-Mg系锌合金血管支架及其制备方法 Download PDFInfo
- Publication number
- CN112891640A CN112891640A CN202110076902.3A CN202110076902A CN112891640A CN 112891640 A CN112891640 A CN 112891640A CN 202110076902 A CN202110076902 A CN 202110076902A CN 112891640 A CN112891640 A CN 112891640A
- Authority
- CN
- China
- Prior art keywords
- zinc alloy
- coating
- intravascular stent
- zinc
- series
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910001297 Zn alloy Inorganic materials 0.000 title claims abstract description 75
- 229910009369 Zn Mg Inorganic materials 0.000 title claims abstract description 17
- 229910007573 Zn-Mg Inorganic materials 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000011248 coating agent Substances 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 22
- 239000011701 zinc Substances 0.000 claims abstract description 22
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000011159 matrix material Substances 0.000 claims abstract description 14
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 13
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 9
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 238000005524 ceramic coating Methods 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000003754 machining Methods 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 108010022355 Fibroins Proteins 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 238000005553 drilling Methods 0.000 claims description 3
- 238000010147 laser engraving Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 2
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 239000012510 hollow fiber Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 abstract description 17
- 230000015556 catabolic process Effects 0.000 abstract description 16
- 239000007943 implant Substances 0.000 abstract description 4
- 239000012535 impurity Substances 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 239000011777 magnesium Substances 0.000 description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 229910045601 alloy Inorganic materials 0.000 description 13
- 239000000956 alloy Substances 0.000 description 13
- 238000005260 corrosion Methods 0.000 description 13
- 230000007797 corrosion Effects 0.000 description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 229910052742 iron Inorganic materials 0.000 description 7
- 229910000861 Mg alloy Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002861 polymer material Substances 0.000 description 4
- PGTXKIZLOWULDJ-UHFFFAOYSA-N [Mg].[Zn] Chemical compound [Mg].[Zn] PGTXKIZLOWULDJ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229910000967 As alloy Inorganic materials 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910000733 Li alloy Inorganic materials 0.000 description 1
- 229910000914 Mn alloy Inorganic materials 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 229910000905 alloy phase Inorganic materials 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 229910002056 binary alloy Inorganic materials 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000001989 lithium alloy Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229910002059 quaternary alloy Inorganic materials 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C18/00—Alloys based on zinc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供了一种Zn‑Mg系锌合金血管支架及其制备方法，所述锌合金血管支架由内部的锌合金基体和外层的可降解涂层构成，所述锌合金基体由Zn、Mg、Li和Mn构成，质量百分比组成为4‑11％Mg，0.15‑0.35％Li，0.7‑1.0％Mn，余量为Zn和不可避免的杂质。本发明所述的锌合金血管支架的力学性质符合医用植入体材料的强度和韧性的要求，无毒，可在人体环境下吸收，能避免二次手术给患者带来的痛苦；所述支架降解分步进行，既保证降解过程中材料的力学性能，又使降解速率和血管支架服役时间相匹配，从而达到可控降解的目的。
Description
技术领域
本发明涉及医用植入材料领域，特别涉及一种Zn-Mg系锌合金血管支架及其制备方法。
背景技术
人体内可降解医用材料正在成为研究和开发的重点，其中可降解高分子材料、纯铁及铁基合金、纯镁及镁基合金是近年研究最为深入的材料。可降解高分子材料强度过低，在临床使用过程中经常会发生断裂等事故，临床适用性受到极大限制。纯铁和铁基合金强度和韧性远高于高分子材料，但是铁降解速度太慢，完全降解可能长达数年。更为严重的是，铁降解过程中生成的铁锈状物质体积膨胀了数倍，并有明显的迁移趋势。纯镁及镁基合金的降解产物无毒、可降解，但其耐蚀性非常差，在人体内很快就会被降解，无法提供足够的力学支撑时间。
腐蚀行为研究表明，与镁、铁相比，锌可能更适宜用作可降解植入材料。锌离子是人体必须的营养元素，参与人体很多的新陈代谢活动，美国临床创新机构推荐人体每天必须摄入2.5到6.4毫克的锌，成年人每天大约摄入300毫克锌，才可能会有一定的毒性反应。研究还发现，锌离子在人体组织中的运输非常迅速，因此锌基可降解植入器械附近不会出现锌富集、细胞毒性或坏死。但是纯Zn的力学性能较差，抗压强度小于20MPa，延伸率仅为0.2％，远远达不到临床的需求，而植入性医疗器械(如骨板骨钉、心脏冠脉支架、外周血管支架等)要求材料在服役期间能够具有足够的力学性能。合金化是提高锌力学性能的有效方法和主要手段，因此，有必要提供一种腐蚀降解速率适宜，机械强度足够的锌合金血管支架。
发明内容
本发明提供了一种Zn-Mg系锌合金血管支架及其制备方法，其目的是为了解决现有植入型锌合金无法兼顾降解速率和机械强度的问题。
为了达到上述目的，本发明的提供了一种Zn-Mg系锌合金血管支架，所述锌合金血管支架由内部的锌合金基体和外层的可降解涂层构成，所述锌合金基体由Zn、Mg、Li和Mn构成，质量百分比组成为6-9％Mg，0.05-0.25％Li，0.5-0.9％Mn，余量为Zn和不可避免的杂质。
进一步的，所述可降解涂层包括高分子材料涂层、陶瓷涂层和药物涂层中的一种或多种。
进一步的，所述高分子材料涂层为聚己酸内酯、聚乳酸、聚羟基戊酸酯、L-聚乳酸、聚氰基丙烯酸酯、丝素蛋白和壳聚糖中的一种或多种；所述陶瓷涂层为羟基磷灰石、磷酸三钙和磷酸氧四钙中的一种或多种；所述药物涂层为负载骨形成蛋白、血管内皮细胞生长因子、辛伐他汀、雷帕霉素、紫杉醇和万古霉素中的一种或多种。
进一步的，所述可降解涂层的厚度为0.01－5mm。
本申请还提供了一种Zn-Mg系锌合金血管支架的制备方法，包括如下步骤：
一、按照锌合金组成进行配料、熔化，再经搅拌、静置和浇注，得到Zn-Mg系锌合金铸锭；
二、将所得锌合金铸锭依次经过外层切削、旋锻、挤出、拉拔和退火，得到具有超塑性特征的锌合金圆柱棒材；
三、将所得锌合金圆柱棒材进行钻孔机械加工、常温拉拔、激光雕刻、化学抛光、涂覆涂层，得到所述的Zn-Mg系锌合金血管支架。
进一步的，所述步骤一中搅拌速率为500-1500r/min，搅拌时间为5-10min。
进一步的，所述步骤一得到的锌合金铸锭为外径40mm*80mm。
进一步的，所述步骤二得到的锌合金棒材外径为15mm。
进一步的，所述步骤三中钻孔机械加工的钻孔内径为12mm。
进一步的，所述步骤三中常温拔拉工艺采用带芯减壁减径拉拔，得到外径2-2.5mm，壁厚0.15-0.20mm的锌合金管材。
本发明的方法利用Zn合金易于腐蚀的特点，选择了Zn-Mg系合金作为可降解材料应用于血管支架。本发明的Zn-Mg系合金的力学性质符合血管支架的强度和韧性的要求，同时又可体内降解，不仅可以克服医用高分子材料强度低和316L不锈钢、钛及钛合金等传统医用金属材料不降解的弱点，还可以克服镁及镁合金降解速率过快导致植入体内力学性能丧失的缺陷，作到兼具有“可生物腐蚀降解特性”和“适宜的腐蚀速率保证提供长期有效的力学支撑”双重特性。
镁在人体中释放出的Mg2+能促进成骨细胞的生长、增殖及分化，具有良好的骨诱导效应。但是，镁在体内是可降解金属，但是其活性很高，在体内降解快，在降解时也会产生氢气，形成气泡，导致愈合和炎症等问题。锌也是可降解的，但速率较慢。现有技术提供了一种含有Mg15.5-48.5wt.％的锌镁合金，用以协调锌和镁的降解性，锌镁合金在体液中的降解速率适宜，既克服了镁降解快，产生氢气泡的问题，也克服了锌降解偏慢，影响骨生长的问题。然而，添加如此大量的镁明显增加了生产成本；而Mn、Li等常作为合金元素少量地添加到锌合金中便可以实现锌合金降解速率的控制，并可以改善锌合金的强度、塑性以及耐腐蚀性。
通过研究Zn基合金相图，发现当Mn含量低于0.5％时，合金的强度提高不明显，当Mn含量超过0.9％时，合金的凝固组织中会出现大量形状不规则的MnZn13第二相颗粒，MnZn13第二相颗粒链状组织，弱化晶界，成为裂纹扩展和应力腐蚀的快速通道，显著降低所述锌合金的塑性和耐蚀性能，加速所述锌合金的降解速度；因此，本发明提出所述锌合金中Mn含量0.5-0.9％，可以显著改善合金的强度、韧性和耐腐蚀性能。
实验发现，将Li加入Zn-Mg-Mn合金，可以起到显著强化基体的效果，且Mn和Li的综合作用可以更显著地增强锌镁合金的强度和塑性。通过研究发现，Zn-Li二元合金中Li含量超过0.5％才能使合金的屈服强度250MPa和抗拉强度〉350MPa，但是在所述Zn-Mg-Mn-Li四元合金中，Li含量在0.05％即可使合金的屈服强度〉250MPa和抗拉强度〉350MPa，这得益于所述Mn和Li的综合作用。发明人还发现，当Li含量超过0.25％之后，虽然Zn-Mg-Mn-Li合金的强度进一步提高，但对合金组织的不均匀性和耐腐蚀性有显著影响，这不利于使用所述锌合金批量制备性能稳定的产品，且加大了对表面光洁度有要求的产品的表面处理难度。因此，综合考虑Li元素加入的利弊，本发明提出所述锌合金中Li含量为0.05-0.25％。
本发明所述的锌合金血管支架的力学性质符合医用植入体材料的强度和韧性的要求，无毒，可在人体环境下吸收，能避免二次手术给患者带来的痛苦；耐蚀性远高于镁合金，降解速度大幅度降低，可提供更长时间的力学支撑，避免血管支架提前失效。另外，其机械强度远高于多聚物，韧性高、易于制造，弹性模量与人体匹配好，可以同时满足高耐蚀性和高强韧两个要求。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚，下面将结合具体实施例进行详细描述。
本发明针对现有的问题，提供了一种Zn-Mg系锌合金血管支架，所述锌合金血管支架由内部的锌合金基体和外层的可降解涂层构成，所述锌合金基体由Zn、Mg、Li和Mn构成，质量百分比组成为4-11％Mg，0.15-0.35％Li，0.7-1.0％Mn，余量为Zn和不可避免的杂质。
所述锌合金血管支架的制备方法包括如下步骤：
一、按照锌合金组成进行配料、熔化，再经搅拌、静置和浇注，得到Zn-Mg系锌合金铸锭；所述搅拌速率为500-1500r/min，搅拌时间为5-10min，所述锌合金铸锭为外径40mm*80mm。
二、将所得锌合金铸锭依次经过外层切削、旋锻、挤出、拉拔和退火，得到具有超塑性特征的锌合金圆柱棒材；经过表层切削、旋锻、挤出后的锌合金棒材外径为15mm。
三、将所得锌合金圆柱棒材进行钻孔机械加工、常温拉拔、激光雕刻、化学抛光、涂覆涂层，得到所述的Zn-Mg系锌合金血管支架。所述锌合金棒材钻孔内径为12mm,所述拉拔工艺在常温下进行，采用带芯减壁减径拔拉，得到外径2-2.5mm，壁厚0.15-0.20mm的锌合金管材。
实施例1
通过上述制备方法得到基体质量百分比组成为6％Mg，0.05％Li，0.5％Mn，余量为Zn，可降解涂层为壳聚糖、药物为紫杉醇的可降解锌合金血管支架。
实施例2
通过上述制备方法得到基体质量百分比组成为9％Mg，0.1％Li，0.6％Mn，余量为Zn，可降解涂层为聚己内酯、药物为肝素的可降解锌合金血管支架。
实施例3
通过上述制备方法得到基体质量百分比组成为8％Mg，0.15％Li，0.7％Mn，余量为Zn，可降解涂层为丝素蛋白、药物为依维莫司的可降解锌合金血管支架。
表1为实施例与对比例力学性能数据结果(可根据需要更改测试的属性)
| 序号 | 实验材料 | 抗拉强度/MPa | 断后伸长率 |
| 1 | 实施例1 | 323 | 46 |
| 2 | 实施例2 | 370 | 49 |
| 3 | 实施例3 | 412 | 37 |
表2为实施例与对比例腐蚀性能数据结果
| 序号 | 实验材料 | 降解速度(毫米/年) |
| 1 | 实施例1 | 0.022 |
| 2 | 实施例2 | 0.027 |
| 3 | 实施例3 | 0.031 |
根据实验数据可见经过多道强化加工工艺改善，锌合金晶粒细化后获得了强韧性较高的合金棒材。本方案制备的锌合金血管支架具有优良的强韧性、延伸率及降解性能，可以提供良好力学性能的同时不需要二次取出，降低患者的痛苦和治疗成本。
以上所述是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明所述原理的前提下，还可以作出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种Zn-Mg系锌合金血管支架，其特征在于，所述锌合金血管支架由内部的锌合金基体和外层的可降解涂层构成，所述锌合金基体由Zn、Mg、Li和Mn构成，质量百分比组成为6-9％Mg，0.05-0.25％Li，0.5-0.9％Mn，余量为Zn。
2.根据权利要求1所述的锌合金血管支架，其特征在于，所述可降解涂层包括高分子材料涂层、陶瓷涂层和药物涂层中的一种或多种。
3.根据权利要求2所述的锌合金血管支架，其特征在于，所述高分子材料涂层为聚己酸内酯、聚乳酸、聚羟基戊酸酯、L-聚乳酸、聚氰基丙烯酸酯、丝素蛋白和壳聚糖中的一种或多种；所述陶瓷涂层为羟基磷灰石、磷酸三钙和磷酸氧四钙中的一种或多种；所述药物涂层为负载骨形成蛋白、血管内皮细胞生长因子、辛伐他汀、雷帕霉素、紫杉醇和万古霉素中的一种或多种。
4.根据权利要求1所述的锌合金血管支架，其特征在于，所述可降解涂层的厚度为0.01－5mm。
5.一种如权利要求1所述的锌合金血管支架的制备方法，其特征在于，所述锌合金血管支架的制备方法包括如下步骤：
一、按照锌合金组成进行配料、熔化，再经搅拌、静置和浇注，得到Zn-Mg系锌合金铸锭；
二、将所得锌合金铸锭依次经过外层切削、旋锻、挤出、拉拔和退火，得到具有超塑性特征的锌合金圆柱棒材；
三、将所得锌合金圆柱棒材进行钻孔机械加工、常温拉拔、激光雕刻、化学抛光、涂覆涂层，得到所述的Zn-Mg系锌合金血管支架。
6.根据权利要求5所述的制备方法，其特征在于，所述步骤一中搅拌速率为500-1500r/min，搅拌时间为5-10min。
7.根据权利要求5所述的制备方法，其特征在于，所述步骤一得到的锌合金铸锭为外径40mm*80mm。
8.根据权利要求5所述的制备方法，其特征在于，所述步骤二得到的锌合金棒材外径为15mm。
9.根据权利要求5所述的制备方法，其特征在于，所述步骤三中钻孔机械加工的钻孔内径为12mm。
10.根据权利要求5所述的制备方法，其特征在于，所述步骤三中常温拔拉工艺采用带芯减壁减径拉拔，得到外径2-2.5mm，壁厚0.15-0.20mm的锌合金管材。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110076902.3A CN112891640B (zh) | 2021-01-20 | 2021-01-20 | 一种Zn-Mg系锌合金血管支架及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110076902.3A CN112891640B (zh) | 2021-01-20 | 2021-01-20 | 一种Zn-Mg系锌合金血管支架及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112891640A true CN112891640A (zh) | 2021-06-04 |
| CN112891640B CN112891640B (zh) | 2022-06-28 |
Family
ID=76116884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110076902.3A Active CN112891640B (zh) | 2021-01-20 | 2021-01-20 | 一种Zn-Mg系锌合金血管支架及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112891640B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113528870A (zh) * | 2021-07-15 | 2021-10-22 | 东南大学 | 一种可降解Zn-Li-X系合金丝材及其制备方法 |
| CN113975470A (zh) * | 2021-11-22 | 2022-01-28 | 山东瑞安泰医疗技术有限公司 | 一种可降解金属钼基合金血管内支架制备方法 |
| CN115068689A (zh) * | 2022-06-17 | 2022-09-20 | 北京邦塞科技有限公司 | 骨填充囊袋及其制备方法和应用 |
| CN116920180A (zh) * | 2023-09-14 | 2023-10-24 | 乐普（北京）医疗器械股份有限公司 | 一种可降解金属材料及其制备方法与应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1835043A1 (en) * | 2006-03-18 | 2007-09-19 | Acrostak Corp. | Magnesium-based alloy with improved combination of mechanical and corrosion characteristics |
| CN101385660A (zh) * | 2007-09-12 | 2009-03-18 | 中国科学院金属研究所 | 一种可生物降解的颅骨修补体 |
| WO2010034098A1 (en) * | 2008-09-24 | 2010-04-01 | Integran Technologies, Inc. | In-vivo biodegradable medical implant |
| US20100119582A1 (en) * | 2003-02-22 | 2010-05-13 | Lars Boerger | Device for the Treatment and Prevention of Disease, and Methods Related Thereto |
| CN107456610A (zh) * | 2016-06-02 | 2017-12-12 | 北京大学 | 一种Zn-Ag系锌合金及其制备方法与应用 |
| CN108277386A (zh) * | 2018-03-23 | 2018-07-13 | 北京大学 | 一种Zn-Li-Mg系锌合金及其制备方法与应用 |
| CN108815589A (zh) * | 2018-03-27 | 2018-11-16 | 乐普（北京）医疗器械股份有限公司 | 一种医用可降解锌基合金血管支架制品 |
-
2021
- 2021-01-20 CN CN202110076902.3A patent/CN112891640B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100119582A1 (en) * | 2003-02-22 | 2010-05-13 | Lars Boerger | Device for the Treatment and Prevention of Disease, and Methods Related Thereto |
| EP1835043A1 (en) * | 2006-03-18 | 2007-09-19 | Acrostak Corp. | Magnesium-based alloy with improved combination of mechanical and corrosion characteristics |
| CN101385660A (zh) * | 2007-09-12 | 2009-03-18 | 中国科学院金属研究所 | 一种可生物降解的颅骨修补体 |
| WO2010034098A1 (en) * | 2008-09-24 | 2010-04-01 | Integran Technologies, Inc. | In-vivo biodegradable medical implant |
| CN107456610A (zh) * | 2016-06-02 | 2017-12-12 | 北京大学 | 一种Zn-Ag系锌合金及其制备方法与应用 |
| CN108277386A (zh) * | 2018-03-23 | 2018-07-13 | 北京大学 | 一种Zn-Li-Mg系锌合金及其制备方法与应用 |
| CN108815589A (zh) * | 2018-03-27 | 2018-11-16 | 乐普（北京）医疗器械股份有限公司 | 一种医用可降解锌基合金血管支架制品 |
Non-Patent Citations (2)
| Title |
|---|
| 郑玉峰等: "血管支架用可降解金属研究进展", 《金属学报》 * |
| 郑玉峰等: "血管支架用可降解金属研究进展", 《金属学报》, no. 10, 11 October 2017 (2017-10-11) * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113528870A (zh) * | 2021-07-15 | 2021-10-22 | 东南大学 | 一种可降解Zn-Li-X系合金丝材及其制备方法 |
| CN113975470A (zh) * | 2021-11-22 | 2022-01-28 | 山东瑞安泰医疗技术有限公司 | 一种可降解金属钼基合金血管内支架制备方法 |
| CN113975470B (zh) * | 2021-11-22 | 2023-09-22 | 山东瑞安泰医疗技术有限公司 | 一种可降解金属钼基合金血管内支架制备方法 |
| CN115068689A (zh) * | 2022-06-17 | 2022-09-20 | 北京邦塞科技有限公司 | 骨填充囊袋及其制备方法和应用 |
| CN115068689B (zh) * | 2022-06-17 | 2024-01-19 | 北京邦塞科技有限公司 | 骨填充囊袋及其制备方法和应用 |
| CN116920180A (zh) * | 2023-09-14 | 2023-10-24 | 乐普（北京）医疗器械股份有限公司 | 一种可降解金属材料及其制备方法与应用 |
| CN116920180B (zh) * | 2023-09-14 | 2023-12-15 | 乐普（北京）医疗器械股份有限公司 | 一种可降解金属材料及其制备方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112891640B (zh) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112891640B (zh) | 一种Zn-Mg系锌合金血管支架及其制备方法 | |
| Venezuela et al. | The influence of alloying and fabrication techniques on the mechanical properties, biodegradability and biocompatibility of zinc: A comprehensive review | |
| JP6816069B2 (ja) | マグネシウム合金、その製造方法およびその使用 | |
| Hermawan et al. | Metals for biomedical applications | |
| EP2764130B1 (en) | Biodegradable metal alloys | |
| CN107496993B (zh) | 一种医用可降解植入性金属材料 | |
| EP2744532B1 (de) | Resorbierbare stents, welche eine magnesiumlegierung enthalten | |
| EP2000551B1 (en) | Magnesium-based alloys | |
| RU2647951C2 (ru) | Магниевый сплав, способ его производства и использования | |
| JP2019019412A (ja) | マグネシウム合金、その製造方法およびその使用 | |
| US10960110B2 (en) | Iron-based biodegradable metals for implantable medical devices | |
| WO2011160534A1 (zh) | 体内可降解的镁合金血管支架材料及其制造方法 | |
| CN110144503B (zh) | 一种高强韧耐蚀镁合金及其制备方法 | |
| Wang et al. | Research progress of biodegradable magnesium-based biomedical materials: A review | |
| WO2017084363A1 (zh) | 医用可降解Zn-Cu-X合金材料及其制备方法 | |
| CN104212998A (zh) | 一种Zn-Mg系锌合金及其制备方法与应用 | |
| CN101015711A (zh) | 一种可体液降解的医用植入体及其制备方法 | |
| CN109602960B (zh) | 一种具备超塑性的医用锌合金棒材制备方法 | |
| EP3229852B1 (en) | ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONS | |
| EP3818995A1 (en) | Degradable spiral coated stent with controllable gradient, preparation method therefor and use thereof | |
| JPWO2015147183A1 (ja) | 亜鉛合金管材とその製造方法、及びそれを用いてなるステントとその製造方法 | |
| CN109939271B (zh) | 一种医用生物可降解锌合金支架的涂层结构及其制备方法 | |
| Liu et al. | Recent progress on Mg-and Zn-based alloys for biodegradable vascular stent applications | |
| CN108543118B (zh) | 体内可控降解的镁合金固定螺钉 | |
| EP3395971B1 (en) | Alloy material and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No. 58 Jinshui West Road, Ningxiang High tech Industrial Park, Changsha City, Hunan Province, 410604 Patentee after: Hunan Huarui Technology Group Co.,Ltd. Country or region after: Zhong Guo Address before: No. 40601-40610, Zhongchuang space, 4 / F, comprehensive building, science and Technology Industrial Park, Hunan University, No. 001, Jinzhou North Road, Ningxiang high tech Industrial Park, Changsha City, Hunan Province, 410600 Patentee before: Hunan Huarui Technology Group Co.,Ltd. Country or region before: Zhong Guo |